ملاجظات دندانپزشکی بیماری های سیستمیک

4. TYPETYPE SYSTOLSYSTOL DIASTOLDIASTOL STAGESTAGE
HIGHHIGH
NORMALNORMAL
13-13/913-13/9 8/5-8/98/5-8/9 ------------------
MILDMILD 14-15/914-15/9 9-9/99-9/9 11
MODERATEMODERATE 16-17/916-17/9 10-10/910-10/9 22
SEVERESEVERE 18-20/918-20/9 11-11/911-11/9 33
VERYVERY
SEVERESEVERE
>21>21 >12>12 44

5. 





6. 



ACEI
SYMPATHOLYTICS


8. 




9. 
2-52-51
SEDATION




10. 2-3RATE
35-6

1-2

11. 

MI6
STROK6
UNSTABLE
BYPASS3
CHF


12. 



13. 
NSAIDS



15. 


30-50


16. 








17. 

pulmunary


18. 









19. 


Roths spot
Oslers node
Janeway lesions



20. 
ESR
CRP
Ig
RF30-50%


21. 



22. 






24. 50-85%50-85%
8888
8-808-80
4040
17-5017-50
60-8060-80
nonvitalnonvital 00
20-4020-40

25. 



26. 




27. Bypass surgery



Cardiac pacemaker

28. 


Root planing
Probing
Implant
Reimplantation of avulsed tooth
apex



29. 


post






Orthodontics adjustment

30. 
21

501

31. 
6001

101

32. 
2

50

600
10

33. 


34. 
535-45
52

35. MI15




36. 15


37. 
CK4-848-72
MB-CK20

39. 





1-2



40. 1



INR5/3PT5/2

41. 


42. T3,T4
:







43. 















44. TESTTEST HYPERHYPER NORMALNORMAL HYPOHYPO
T4T4 ELEVATEDELEVATED 60-15060-150 DECREASEDDECREASED
T3T3 ELEVATEDELEVATED 70-19070-190 DECREASEDDECREASED
TSHTSH NONE OR VERYNONE OR VERY
DECREASEDDECREASED 0.3-5.00.3-5.0 ELEVATEDELEVATED
TBGTBG ELEVATEDELEVATED 12-3012-30 DECREASEDDECREASED
rT3rT3 ELEVATEDELEVATED 10-4010-40 DECREASEDDECREASED
FT4FT4 ELEVATEDELEVATED 1.3-3.81.3-3.8 DECREASEDDECREASED
FT3FT3 ELEVATEDELEVATED 260-480260-480 DECREASEDDECREASED
RAIURAIU ELEVATEDELEVATED 10%-30%PER24HR10%-30%PER24HR DECREASEDDECREASED

45. PROPYLTHIOURACIL 100-150 MG 8HR
METHIMAZOLE 10-20 MG 8HR
PROPRANOLOL 20-40 MG 6HR
DEXAMETHASONE 2 MG 6HR

PROPYLTHIOURACIL 50-100MG 8HR

46. 




47. 
100-300




------------------------------------------------------




48. 3





49. 

50. 













51. LEVOTHYROXINE 75-112 MICRO PER DAY
WOMEN
125-200MEN

52. CNS



54. 3



55. 

12


56. 
IDDM:

57. 



58. 
FBS140
2200



59. 6-8
4-8
5/7
9/7-9/8

60. 

NIDDM
IDDMBRITTLE DIABETS






62. 
3


63. COPD:
50

60

64. 
SEMISUPINEUPRIGHT





65. 








66. 
INHALER

SEDATION






3/0-5/0